troglitazone has been researched along with Fibrosis in 14 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect of the PPAR-gamma agonist troglitazone on transforming growth factor (TGF)-beta1-induced collagen type I expression in keloid fibroblasts." | 7.75 | Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts. ( Chen, XL; Gao, WY; Guo, SZ; Li, X; Li, ZJ; Ma, B; Yi, CG; Zhang, GY, 2009) |
| " We determined the influence of troglitazone, a ligand for PPAR-gamma, on pancreatic damage and fibrosis in experimental chronic pancreatitis." | 7.73 | Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. ( Bruno, MJ; Daalhuisen, J; de Boer, AM; de Vos, AF; Florquin, S; van der Poll, T; van Westerloo, DJ, 2005) |
| "We have previously reported that troglitazone inhibits proinflammatory cytokine production in chronic pancreatitis." | 7.72 | Troglitazone inhibits the progression of chronic pancreatitis and the profibrogenic activity of pancreatic stellate cells via a PPARgamma-independent mechanism. ( Kawamata, H; Kobayashi, M; Shimizu, K; Shiratori, K, 2004) |
| "Troglitazone and rosiglitazone suppress TGF-β1-induced synthesis of procollagen1A1, fibronectin, and α-smooth muscle actin in HIFs and may be useful in treating intestinal fibrosis." | 3.85 | Anti-fibrogenic effect of PPAR-γ agonists in human intestinal myofibroblasts. ( Hahm, KB; Hong, SP; Jung, Y; Kim, DH; Kim, G; Kim, JW; Koo, JB; Lee, KJ; Lee, KM; Nam, MO; Shin, SJ; Yoo, J; Yoo, JH, 2017) |
| " Therefore, we investigated the anti-fibrotic and anti-inflammatory effects of the TZD troglitazone in the mouse model of unilateral ureteral obstruction (UUO)." | 3.75 | PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. ( Arakawa, T; Doi, S; Doi, T; Kawai, T; Kohno, N; Masaki, T; Yokoyama, Y; Yorioka, N, 2009) |
| "To investigate the effect of the PPAR-gamma agonist troglitazone on transforming growth factor (TGF)-beta1-induced collagen type I expression in keloid fibroblasts." | 3.75 | Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts. ( Chen, XL; Gao, WY; Guo, SZ; Li, X; Li, ZJ; Ma, B; Yi, CG; Zhang, GY, 2009) |
| " The present study was conducted to examine whether troglitazone (TGZ) can inhibit TGFbeta2-mediated fibrosis of RPE cells." | 3.74 | Troglitazone suppresses transforming growth factor beta-mediated fibrogenesis in retinal pigment epithelial cells. ( Chen, SL; Cheng, HC; Ho, TC; Hong, KF; Lai, HY; Tsao, YP, 2008) |
| " We determined the influence of troglitazone, a ligand for PPAR-gamma, on pancreatic damage and fibrosis in experimental chronic pancreatitis." | 3.73 | Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. ( Bruno, MJ; Daalhuisen, J; de Boer, AM; de Vos, AF; Florquin, S; van der Poll, T; van Westerloo, DJ, 2005) |
| "We have previously reported that troglitazone inhibits proinflammatory cytokine production in chronic pancreatitis." | 3.72 | Troglitazone inhibits the progression of chronic pancreatitis and the profibrogenic activity of pancreatic stellate cells via a PPARgamma-independent mechanism. ( Kawamata, H; Kobayashi, M; Shimizu, K; Shiratori, K, 2004) |
| "Pulmonary fibrosis is characterized by alterations in fibroblast phenotypes resulting in excessive extracellular matrix accumulation and anatomic remodeling." | 1.35 | PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. ( Gangireddy, SR; Hogaboam, CM; Hu, B; Keshamouni, VG; Milam, JE; Phan, SH; Reddy, RC; Standiford, TJ; Thannickal, VJ, 2008) |
| "Troglitazone treatment significantly increased pancreatic wet weight and protein, DNA, and enzyme contents compared with those in the control rats." | 1.31 | Troglitazone stimulates pancreatic growth in congenitally CCK-A receptor-deficient OLETF rats. ( Akiyama, T; Fukumitsu, KI; Jia, DM; Otsuki, M; Tabaru, A, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Jeon, KI | 3 |
| Kumar, A | 1 |
| Callan, CL | 1 |
| DeMagistris, M | 1 |
| MacRae, S | 1 |
| Nehrke, K | 1 |
| Huxlin, KR | 3 |
| Koo, JB | 1 |
| Nam, MO | 1 |
| Jung, Y | 1 |
| Yoo, J | 1 |
| Kim, DH | 1 |
| Kim, G | 1 |
| Shin, SJ | 1 |
| Lee, KM | 1 |
| Hahm, KB | 1 |
| Kim, JW | 1 |
| Hong, SP | 1 |
| Lee, KJ | 1 |
| Yoo, JH | 1 |
| Phipps, RP | 2 |
| Sime, PJ | 2 |
| Kulkarni, A | 1 |
| Woeller, CF | 1 |
| Hindman, HB | 1 |
| Kawai, T | 1 |
| Masaki, T | 1 |
| Doi, S | 1 |
| Arakawa, T | 1 |
| Yokoyama, Y | 1 |
| Doi, T | 1 |
| Kohno, N | 1 |
| Yorioka, N | 1 |
| Shimizu, K | 2 |
| Zhang, GY | 1 |
| Yi, CG | 1 |
| Li, X | 1 |
| Ma, B | 1 |
| Li, ZJ | 1 |
| Chen, XL | 1 |
| Guo, SZ | 1 |
| Gao, WY | 1 |
| Shiratori, K | 1 |
| Kobayashi, M | 1 |
| Kawamata, H | 1 |
| van Westerloo, DJ | 1 |
| Florquin, S | 1 |
| de Boer, AM | 1 |
| Daalhuisen, J | 1 |
| de Vos, AF | 1 |
| Bruno, MJ | 1 |
| van der Poll, T | 1 |
| Milam, JE | 1 |
| Keshamouni, VG | 1 |
| Phan, SH | 1 |
| Hu, B | 1 |
| Gangireddy, SR | 1 |
| Hogaboam, CM | 1 |
| Standiford, TJ | 1 |
| Thannickal, VJ | 1 |
| Reddy, RC | 1 |
| Cheng, HC | 1 |
| Ho, TC | 1 |
| Chen, SL | 1 |
| Lai, HY | 1 |
| Hong, KF | 1 |
| Tsao, YP | 1 |
| Inoue, Y | 1 |
| Tanigawa, K | 1 |
| Nakamura, S | 1 |
| Xu, G | 1 |
| Kawaguchi, M | 1 |
| Kato, Y | 1 |
| Tamura, K | 1 |
| McCarthy, KJ | 1 |
| Routh, RE | 1 |
| Shaw, W | 1 |
| Walsh, K | 1 |
| Welbourne, TC | 1 |
| Johnson, JH | 1 |
| Jia, DM | 1 |
| Fukumitsu, KI | 1 |
| Tabaru, A | 1 |
| Akiyama, T | 1 |
| Otsuki, M | 1 |
1 review available for troglitazone and Fibrosis
| Article | Year |
|---|---|
Mechanisms of pancreatic fibrosis and applications to the treatment of chronic pancreatitis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Antioxidants; Cell Prolife | 2008 |
13 other studies available for troglitazone and Fibrosis
| Article | Year |
|---|---|
Blocking Mitochondrial Pyruvate Transport Alters Corneal Myofibroblast Phenotype: A New Target for Treating Fibrosis.
Topics: Actins; Animals; Cats; Cells, Cultured; Fibroblasts; Fibrosis; Myofibroblasts; Phenotype; PPAR gamma | 2023 |
Anti-fibrogenic effect of PPAR-γ agonists in human intestinal myofibroblasts.
Topics: Actins; Cells, Cultured; Chromans; Extracellular Matrix Proteins; Fibrosis; Gene Expression; Humans; | 2017 |
Antifibrotic Actions of Peroxisome Proliferator-Activated Receptor γ Ligands in Corneal Fibroblasts Are Mediated by β-Catenin-Regulated Pathways.
Topics: Actins; Animals; beta Catenin; Cats; Chromans; Collagen Type I; Cornea; Fibroblasts; Fibronectins; F | 2017 |
Inhibitory effects of PPARγ ligands on TGF-β1-induced corneal myofibroblast transformation.
Topics: Actins; Animals; Cats; Cell Line, Transformed; Cell Nucleus; Chromans; Collagen Type I; Cornea; Fibr | 2014 |
PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta.
Topics: Actins; Animals; Anti-Inflammatory Agents; Arterioles; Blood Glucose; Cell Proliferation; Chromans; | 2009 |
Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts.
Topics: Adolescent; Adult; Blotting, Western; Chromans; Collagen Type I; Female; Fibroblasts; Fibrosis; Huma | 2009 |
Troglitazone inhibits the progression of chronic pancreatitis and the profibrogenic activity of pancreatic stellate cells via a PPARgamma-independent mechanism.
Topics: Actins; Animals; Cell Division; Cells, Cultured; Chromans; Chronic Disease; Disease Progression; Dru | 2004 |
Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice.
Topics: Actins; Animals; Cell Differentiation; Ceruletide; Chromans; Chronic Disease; Collagen; Disease Mode | 2005 |
PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis.
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Cell Differentiation; Cell Division; Cells, Culture | 2008 |
Troglitazone suppresses transforming growth factor beta-mediated fibrogenesis in retinal pigment epithelial cells.
Topics: Cell Line; Cell Movement; Chromans; Collagen Type I; Enzyme Activation; Fibronectins; Fibrosis; Huma | 2008 |
Lack of effect of CS-045, a new antidiabetic agent, on insulin secretion in the remnant pancreas after 90% pancreatectomy in rats.
Topics: Animals; Blood Glucose; Chromans; Fibrosis; Glucose Tolerance Test; Hypoglycemic Agents; In Vitro Te | 1995 |
Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion.
Topics: Animals; Basement Membrane; Body Weight; Chondroitin Sulfate Proteoglycans; Chromans; Diabetes Melli | 2000 |
Troglitazone stimulates pancreatic growth in congenitally CCK-A receptor-deficient OLETF rats.
Topics: Aging; Amylases; Animals; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Fibrosis; Homeostasis; | 2001 |